Vaccines Sales Market Report 2020-2030

Table of Content

---

1. Report Overview

1.1 Why You Should Buy This Report

1.2 How This Report Delivers

1.3 Key Questions Answered by This Analytical Report Include:

1.4 Who is This Report For?

1.5 Methodology

1.5.1 Primary Research

1.5.2 Secondary Research

1.5.3 Data Sources

1.6 Market Evaluation & Forecasting Methodology

1.7 COIVD-19 Impact Recovery Pattern Analysis

1.7.1 V-Shaped Recovery

1.7.2 U-Shaped Recovery

1.7.3 W-Shaped Recovery

1.7.4 L-Shaped Recovery

1.8 Frequently Asked Questions (FAQ)

2. Executive Summary

2.1.1 Growing Demand for Bacterial Type to Dominate the Market

2.1.1.1 Due to higher sales of pneumococcal, meningitis and DTP worldwide, the segment of bacterial diseases has a dominant market share

2.1.2 By Age Group Analysis

2.1.3 By Distribution Channel Analysis

2.1.4 Regional Market Insight

 

3. Vaccine Industry Overview

3.1 Industry Definitions

3.2 Immune System and Vaccines

3.3 How Vaccines Work

3.4 Types of Immunity

3.4.1 Active Immunity

3.4.2 Passive Immunity

3.4.3 Advantages of Vaccination

3.5 History of Vaccines

3.6 Rapid Manufacturing for Pandemics

3.6.1 Types of Vaccine Manufacturing Methods

 

4. Market Dynamics

4.1 Vaccine Development and Distribution Amid the COVID-19 Pandemic

4.2 Market Growth Driving Factors

4.2.1 Growing Vaccines Supply by UNICEF, WHO, PAHO to Aid Immunization Process

4.2.2 Strong Supply Backed Up by Robust R&D to Drive the Market

4.2.3 Competitive Pipeline to Expand the Market Value During the Forecast Period

4.2.4 Technological Advancements such as Rapid Manufacturing and Others

4.2.5 Rising Immunization Across the Globe

4.2.6 Government Support for Vaccine Development

4.3 Market Growth Restraining Factors

4.3.1 High Cost Associated with Vaccine Dose to Limit Adoption

4.3.2 Lack of Awareness in Low-Income Countries

4.3.1 High Prices of Vaccines

4.3.1 Rising Concerns of Associated Risk Factors

4.3.2 Inadequate Vaccine Supply

4.4 Growth Opportunities in the Global Market

4.4.1 RNA Vaccination

4.4.2 Rise of Antibiotic Resistance

4.4.3 Current Situation

4.4.4 Development and Launch of New Vaccines

4.4.5 Increased R&D Efforts

4.4.6 Increased Demand from Emerging Markets

4.4.7 Government Initiatives for Increased Immunizations

4.4.8 Global Alliance for Vaccines and Immunization (GAVI)

4.4.9 Improving access to sustainable immunization services.

4.4.10 Undulating Demand

4.4.11 Supply Restraints

4.4.12 Funding Trends

4.4.13 Protecting the Workforce of an Economy

4.5 SWOT Analysis of the World Human Vaccines Market

4.5.1 Strengths

4.5.2 Weaknesses

4.5.3 Opportunities

4.5.4 Threats

4.6 STEP Analysis of the World Human Vaccines Industry and Market

4.6.1 Social Factors

4.6.2 Technological Forces

4.6.3 Economic Factors

4.6.4 Political Factors

 

5. COVID-19 Impact Analysis

5.1 Research and Development on COVID-19

 

6. Global Vaccines Sales Market Outlook

6.1 Market Overview

6.2 Market in Terms of Value

6.2.1 Market in Terms of Value (Normal Recovery)

6.2.2 Market in Terms of Value (V-Shaped Recovery)

6.2.3 Market in Terms of Value (W-Shaped Recovery)

6.2.4 Market in Terms of Value (U-Shaped Recovery)

6.3 Global Market Breakdown by Region

6.3.1.1 North America is expected to dominate the global market during the forecast period

6.3.1 Market in Terms of Value (Normal Recovery)

6.3.2 Market in Terms of Value (V-Shaped Recovery)

6.3.3 Market in Terms of Value (W-Shaped Recovery)

6.3.4 Market in Terms of Value (U-Shaped Recovery)

6.3.5 Market in Terms of Value (L-Shaped Recovery)

6.4 Global Market Breakdown by Disease Type

6.4.1.1 Bacterial Diseases the segment held the significant share in the overall market and is expected to offer an opportunity throughout the forecast period

6.4.1 Market in Terms of Value (Normal Recovery)

6.4.2 Market in Terms of Value (V-Shaped Recovery)

6.4.3 Market in Terms of Value (W-Shaped Recovery)

6.4.4 Market in Terms of Value (U-Shaped Recovery)

6.4.5 Market in Terms of Value (L-Shaped Recovery)

6.5 Global Market Breakdown by Viral Diseases

6.5.1.1 Hepatitis Segment is expected to have the highest CAGR during forecast period.

6.5.1 Human Diseases

6.5.1 Market in Terms of Value (Normal Recovery)

6.5.2 Market in Terms of Value (V-Shaped Recovery)

6.5.3 Market in Terms of Value (W-Shaped Recovery)

6.5.4 Market in Terms of Value (U-Shaped Recovery)

6.5.5 Market in Terms of Value (L-Shaped Recovery)

6.6 Global Market Breakdown by Vaccine Type

6.6.1 Recombinant/Conjugate/Subunit the segment held the significant share

6.6.2 Inactivated (Killed) Vaccines

6.6.3 Toxoid Vaccines

6.6.4 Subunit Vaccines

6.6.5 Conjugate Vaccines

6.6.6 Recombinant Vector Vaccines

6.6.7 DNA Vaccines

6.6.8 RNA Vaccines

6.6.9 Adjuvants and Excipients

6.6.10 Pathogen Components

6.6.11 Particulate Adjuvants

6.6.12 Other/Combination Vaccines

6.6.13 Market in Terms of Value (Normal Recovery)

6.6.14 Market in Terms of Value (V-Shaped Recovery)

6.6.15 Market in Terms of Value (W-Shaped Recovery)

6.6.16 Market in Terms of Value (U-Shaped Recovery)

6.6.17 Market in Terms of Value (L-Shaped Recovery)

6.7 Global Market Breakdown by Bacterial Disease

6.7.1.1 Pneumococcal Disease is expected to offer an opportunity throughout the forecast period

6.7.1 Market in Terms of Value (Normal Recovery)

6.7.2 Market in Terms of Value (V-Shaped Recovery)

6.7.3 Market in Terms of Value (W-Shaped Recovery)

6.7.4 Market in Terms of Value (U-Shaped Recovery)

6.7.5 Market in Terms of Value (L-Shaped Recovery)

6.8 Global Market Breakdown by Distribution Channel

6.8.1.1 A dominant share of the income is anticipated for hospital and retail pharmacies

6.8.1 Market in Terms of Value (Normal Recovery)

6.8.2 Market in Terms of Value (V-Shaped Recovery)

6.8.3 Market in Terms of Value (W-Shaped Recovery)

6.8.4 Market in Terms of Value (U-Shaped Recovery)

6.8.5 Market in Terms of Value (L-Shaped Recovery)

6.9 Global Market Breakdown by Age Group

6.9.1 Pediatric Vaccines

6.9.2 Paediatric Vaccine Trends

6.9.3 Prenatal Vaccines

6.9.4 Market in Terms of Value (Normal Recovery)

6.9.5 Market in Terms of Value (V-Shaped Recovery)

6.9.6 Market in Terms of Value (W-Shaped Recovery)

6.9.7 Market in Terms of Value (U-Shaped Recovery)

6.9.8 Market in Terms of Value (L-Shaped Recovery)

 

7. North America Vaccines Sales Market Outlook

7.1.1 Growth attributed to vaccination compulsion or mandate

7.1 North America Market Overview

7.2 North America Market in Terms of Value

7.2.1 Market in Terms of Value (Normal Recovery)

7.2.2 Market in Terms of Value (V-Shaped Recovery)

7.2.3 Market in Terms of Value (W-Shaped Recovery)

7.2.4 Market in Terms of Value (U-Shaped Recovery)

7.2.5 Market in Terms of Value (L-Shaped Recovery)

7.3 North America Market Breakdown by Country

7.3.1 Market in Terms of Value (Normal Recovery)

7.3.2 Market in Terms of Value (V-Shaped Recovery)

7.3.3 Market in Terms of Value (W-Shaped Recovery)

7.3.4 Market in Terms of Value (U-Shaped Recovery)

7.3.5 Market in Terms of Value (L-Shaped Recovery)

7.4 U.S. Vaccine Sales Market Outlook

7.4.1.1 The country is expected to offer an opportunity throughout the forecast period

7.4.1 Market in Terms of Value (Normal Recovery)

7.4.2 Market in Terms of Value (V-Shaped Recovery)

7.4.3 Market in Terms of Value (W-Shaped Recovery)

7.4.4 Market in Terms of Value (U-Shaped Recovery)

7.4.5 Market in Terms of Value (L-Shaped Recovery)

7.5 Canada Vaccine Sales Market Outlook

7.5.1.1 Market is supported by consistent and sustained funding of immunization programs

7.5.1 Market in Terms of Value (Normal Recovery)

7.5.2 Market in Terms of Value (V-Shaped Recovery)

7.5.3 Market in Terms of Value (W-Shaped Recovery)

7.5.4 Market in Terms of Value (U-Shaped Recovery)

7.5.5 Market in Terms of Value (L-Shaped Recovery)

7.6 North America Market Breakdown by Disease Type

7.6.1 Market in Terms of Value (Normal Recovery)

7.6.2 Market in Terms of Value (V-Shaped Recovery)

7.6.3 Market in Terms of Value (W-Shaped Recovery)

7.6.4 Market in Terms of Value (U-Shaped Recovery)

7.6.5 Market in Terms of Value (L-Shaped Recovery)

7.7 North America Market Breakdown by Viral Diseases

7.7.1 Market in Terms of Value (Normal Recovery)

7.7.2 Market in Terms of Value (V-Shaped Recovery)

7.7.3 Market in Terms of Value (W-Shaped Recovery)

7.7.4 Market in Terms of Value (U-Shaped Recovery)

7.7.5 Market in Terms of Value (L-Shaped Recovery)

7.8 North America Market Breakdown by Vaccine Type

7.8.1 Market in Terms of Value (Normal Recovery)

7.8.2 Market in Terms of Value (V-Shaped Recovery)

7.8.3 Market in Terms of Value (W-Shaped Recovery)

7.8.4 Market in Terms of Value (U-Shaped Recovery)

7.8.5 Market in Terms of Value (L-Shaped Recovery)

7.9 North America Market Breakdown by Bacterial Disease

7.9.1 Market in Terms of Value (Normal Recovery)

7.9.2 Market in Terms of Value (V-Shaped Recovery)

7.9.3 Market in Terms of Value (W-Shaped Recovery)

7.9.4 Market in Terms of Value (U-Shaped Recovery)

7.9.5 Market in Terms of Value (L-Shaped Recovery)

7.10 North America Market Breakdown by Distribution Channel

7.10.1 Market in Terms of Value (Normal Recovery)

7.10.2 Market in Terms of Value (V-Shaped Recovery)

7.10.3 Market in Terms of Value (W-Shaped Recovery)

7.10.4 Market in Terms of Value (U-Shaped Recovery)

7.10.5 Market in Terms of Value (L-Shaped Recovery)

7.11 North America Market Breakdown by Age Group

7.11.1 Market in Terms of Value (Normal Recovery)

7.11.2 Market in Terms of Value (V-Shaped Recovery)

7.11.3 Market in Terms of Value (W-Shaped Recovery)

7.11.4 Market in Terms of Value (U-Shaped Recovery)

7.11.5 Market in Terms of Value (L-Shaped Recovery)

 

8. Europe Vaccines Sales Market Outlook

8.1 Europe Market Overview

8.1.1 A considerable growth in the vaccine market is expected in the European region.

8.2 Europe Market in Terms of Value

8.2.1 Market in Terms of Value (Normal Recovery)

8.2.2 Market in Terms of Value (V-Shaped Recovery)

8.2.3 Market in Terms of Value (W-Shaped Recovery)

8.2.4 Market in Terms of Value (U-Shaped Recovery)

8.2.5 Market in Terms of Value (L-Shaped Recovery)

8.3 Europe Market Breakdown by Country

8.3.1 Market in Terms of Value (Normal Recovery)

8.3.2 Market in Terms of Value (V-Shaped Recovery)

8.3.3 Market in Terms of Value (W-Shaped Recovery)

8.3.4 Market in Terms of Value (U-Shaped Recovery)

8.3.5 Market in Terms of Value (L-Shaped Recovery)

8.4 Russia Vaccine Sales Market Outlook

8.4.1.1 The Russian Federation has purchased over 90% of the total supply of the vaccines in the market

8.4.1 Market in Terms of Value (Normal Recovery)

8.4.2 Market in Terms of Value (V-Shaped Recovery)

8.4.3 Market in Terms of Value (W-Shaped Recovery)

8.4.4 Market in Terms of Value (U-Shaped Recovery)

8.4.5 Market in Terms of Value (L-Shaped Recovery)

8.5 Germany Vaccine Sales Market Outlook

8.5.1.1 Germany is expected to offer an opportunity throughout the forecast period.

8.5.1 Market in Terms of Value (Normal Recovery)

8.5.2 Market in Terms of Value (V-Shaped Recovery)

8.5.3 Market in Terms of Value (W-Shaped Recovery)

8.5.4 Market in Terms of Value (U-Shaped Recovery)

8.5.5 Market in Terms of Value (L-Shaped Recovery)

8.6 UK Vaccine Sales Market Outlook

8.6.1.1 The U.K. is one of the major contributors to the vaccine market

8.6.1 Market in Terms of Value (Normal Recovery)

8.6.1 Market in Terms of Value (V-Shaped Recovery)

8.6.2 Market in Terms of Value (W-Shaped Recovery)

8.6.3 Market in Terms of Value (U-Shaped Recovery)

8.6.4 Market in Terms of Value (L-Shaped Recovery)

8.7 France Vaccine Sales Market Outlook

8.7.1.1 France is one of the major countries to produce vaccines

8.7.1 Market in Terms of Value (Normal Recovery)

8.7.2 Market in Terms of Value (V-Shaped Recovery)

8.7.3 Market in Terms of Value (W-Shaped Recovery)

8.7.4 Market in Terms of Value (U-Shaped Recovery)

8.7.5 Market in Terms of Value (L-Shaped Recovery)

8.8 Italy Vaccine Sales Market Outlook

8.8.1.1 Italy is the fourth largest market for human vaccines within Europe

8.8.1 Market in Terms of Value (Normal Recovery)

8.8.2 Market in Terms of Value (V-Shaped Recovery)

8.8.3 Market in Terms of Value (W-Shaped Recovery)

8.8.4 Market in Terms of Value (U-Shaped Recovery)

8.8.5 Market in Terms of Value (L-Shaped Recovery)

8.9 Rest of Europe Vaccine Sales Market Outlook

8.9.1 Market in Terms of Value (Normal Recovery)

8.9.2 Market in Terms of Value (V-Shaped Recovery)

8.9.3 Market in Terms of Value (W-Shaped Recovery)

8.9.4 Market in Terms of Value (U-Shaped Recovery)

8.9.5 Market in Terms of Value (L-Shaped Recovery)

8.10 Europe Market Breakdown by Disease Type

8.10.1 Market in Terms of Value (Normal Recovery)

8.10.2 Market in Terms of Value (V-Shaped Recovery)

8.10.3 Market in Terms of Value (W-Shaped Recovery)

8.10.4 Market in Terms of Value (U-Shaped Recovery)

8.10.5 Market in Terms of Value (L-Shaped Recovery)

8.11 Europe Market Breakdown by Viral Disease

8.11.1 Market in Terms of Value (Normal Recovery)

8.11.2 Market in Terms of Value (V-Shaped Recovery)

8.11.3 Market in Terms of Value (W-Shaped Recovery)

8.11.4 Market in Terms of Value (U-Shaped Recovery)

8.11.5 Market in Terms of Value (L-Shaped Recovery)

8.12 Europe Market Breakdown by Vaccine Type

8.12.1 Market in Terms of Value (Normal Recovery)

8.12.2 Market in Terms of Value (V-Shaped Recovery)

8.12.3 Market in Terms of Value (W-Shaped Recovery)

8.12.4 Market in Terms of Value (U-Shaped Recovery)

8.12.5 Market in Terms of Value (L-Shaped Recovery)

8.13 Europe Market Breakdown by Bacterial Disease

8.13.1 Market in Terms of Value (Normal Recovery)

8.13.2 Market in Terms of Value (V-Shaped Recovery)

8.13.3 Market in Terms of Value (W-Shaped Recovery)

8.13.4 Market in Terms of Value (U-Shaped Recovery)

8.13.5 Market in Terms of Value (L-Shaped Recovery)

8.14 Europe Market Breakdown by Distribution Channel

8.14.1 Market in Terms of Value (Normal Recovery)

8.14.2 Market in Terms of Value (V-Shaped Recovery)

8.14.3 Market in Terms of Value (W-Shaped Recovery)

8.14.4 Market in Terms of Value (U-Shaped Recovery)

8.14.5 Market in Terms of Value (L-Shaped Recovery)

8.15 Europe Market Breakdown by Age Group

8.15.1 Market in Terms of Value (Normal Recovery)

8.15.2 Market in Terms of Value (V-Shaped Recovery)

8.15.3 Market in Terms of Value (W-Shaped Recovery)

8.15.4 Market in Terms of Value (U-Shaped Recovery)

8.15.5 Market in Terms of Value (L-Shaped Recovery)

 

9. Asia-Pacific Vaccines Sales Market Outlook

9.1 Asia-Pacific Market Overview

9.2 Asia-Pacific Market in Terms of Value

9.2.1 Market in Terms of Value (Normal Recovery)

9.2.2 Market in Terms of Value (V-Shaped Recovery)

9.2.3 Market in Terms of Value (W-Shaped Recovery)

9.2.4 Market in Terms of Value (U-Shaped Recovery)

9.2.5 Market in Terms of Value (L-Shaped Recovery)

9.3 Asia-Pacific Market Breakdown by Country

9.3.1 Market in Terms of Value (Normal Recovery)

9.3.2 Market in Terms of Value (V-Shaped Recovery)

9.3.3 Market in Terms of Value (W-Shaped Recovery)

9.3.4 Market in Terms of Value (U-Shaped Recovery)

9.3.5 Market in Terms of Value (L-Shaped Recovery)

9.4 China Vaccine Sales Market Outlook

9.4.1.1 Growth prospects remain strong in the country

9.4.1 Market in Terms of Value (Normal Recovery)

9.4.2 Market in Terms of Value (V-Shaped Recovery)

9.4.3 Market in Terms of Value (W-Shaped Recovery)

9.4.4 Market in Terms of Value (U-Shaped Recovery)

9.4.5 Market in Terms of Value (L-Shaped Recovery)

9.5 Japan Vaccine Sales Market Outlook

9.5.1.1 Japan is expected to offer an opportunity throughout the forecast period

9.5.1 Market in Terms of Value (Normal Recovery)

9.5.2 Market in Terms of Value (V-Shaped Recovery)

9.5.3 Market in Terms of Value (W-Shaped Recovery)

9.5.4 Market in Terms of Value (U-Shaped Recovery)

9.5.5 Market in Terms of Value (L-Shaped Recovery)

9.6 India Vaccine Sales Market Outlook

9.6.1.1 The prevalence of the diseases has been quite high in India, which is driving the market growth

9.6.1 Market in Terms of Value (Normal Recovery)

9.6.2 Market in Terms of Value (V-Shaped Recovery)

9.6.3 Market in Terms of Value (W-Shaped Recovery)

9.6.4 Market in Terms of Value (U-Shaped Recovery)

9.6.5 Market in Terms of Value (L-Shaped Recovery)

9.7 South Korea Vaccine Sales Market Outlook

9.7.1.1 Korea has been importing all demand for this vaccine due to a lack of homegrown technology to develop a vaccine locally

9.7.1 Market in Terms of Value (Normal Recovery)

9.7.2 Market in Terms of Value (V-Shaped Recovery)

9.7.3 Market in Terms of Value (W-Shaped Recovery)

9.7.4 Market in Terms of Value (U-Shaped Recovery)

9.7.5 Market in Terms of Value (L-Shaped Recovery)

9.8 Australia Vaccine Sales Market Outlook

9.8.1.1 Australia is on track for a record number of flu vaccinations

9.8.1 Market in Terms of Value (Normal Recovery)

9.8.2 Market in Terms of Value (V-Shaped Recovery)

9.8.3 Market in Terms of Value (W-Shaped Recovery)

9.8.4 Market in Terms of Value (U-Shaped Recovery)

9.8.5 Market in Terms of Value (L-Shaped Recovery)

9.9 Rest of Asia-Pacific Vaccine Sales Market Outlook

9.9.1 Market in Terms of Value (Normal Recovery)

9.9.2 Market in Terms of Value (V-Shaped Recovery)

9.9.3 Market in Terms of Value (W-Shaped Recovery)

9.9.4 Market in Terms of Value (U-Shaped Recovery)

9.9.5 Market in Terms of Value (L-Shaped Recovery)

9.10 Asia-Pacific Market Breakdown by Disease Type

9.10.1 Market in Terms of Value (Normal Recovery)

9.10.2 Market in Terms of Value (V-Shaped Recovery)

9.10.3 Market in Terms of Value (W-Shaped Recovery)

9.10.4 Market in Terms of Value (U-Shaped Recovery)

9.10.5 Market in Terms of Value (L-Shaped Recovery)

9.11 Asia-Pacific Market Breakdown by Viral Diseases

9.11.1 Market in Terms of Value (Normal Recovery)

9.11.2 Market in Terms of Value (V-Shaped Recovery)

9.11.3 Market in Terms of Value (W-Shaped Recovery)

9.11.4 Market in Terms of Value (U-Shaped Recovery)

9.11.5 Market in Terms of Value (L-Shaped Recovery)

9.12 Asia-Pacific Market Breakdown by Vaccine Type

9.12.1 Market in Terms of Value (Normal Recovery)

9.12.2 Market in Terms of Value (V-Shaped Recovery)

9.12.3 Market in Terms of Value (W-Shaped Recovery)

9.12.4 Market in Terms of Value (U-Shaped Recovery)

9.12.5 Market in Terms of Value (L-Shaped Recovery)

9.13 Asia-Pacific Market Breakdown by Bacterial Disease

9.13.1 Market in Terms of Value (Normal Recovery)

9.13.2 Market in Terms of Value (V-Shaped Recovery)

9.13.3 Market in Terms of Value (W-Shaped Recovery)

9.13.4 Market in Terms of Value (U-Shaped Recovery)

9.13.5 Market in Terms of Value (L-Shaped Recovery)

9.14 Asia-Pacific Market Breakdown by Distribution Channel

9.14.1 Market in Terms of Value (Normal Recovery)

9.14.2 Market in Terms of Value (V-Shaped Recovery)

9.14.3 Market in Terms of Value (W-Shaped Recovery)

9.14.4 Market in Terms of Value (U-Shaped Recovery)

9.14.5 Market in Terms of Value (L-Shaped Recovery)

9.15 Asia-Pacific Market Breakdown by Age Group

9.15.1 Market in Terms of Value (Normal Recovery)

9.15.2 Market in Terms of Value (V-Shaped Recovery)

9.15.3 Market in Terms of Value (W-Shaped Recovery)

9.15.4 Market in Terms of Value (U-Shaped Recovery)

9.15.5 Market in Terms of Value (L-Shaped Recovery)

 

10. Middle East & Africa Vaccines Sales Market Outlook

10.1 Middle East & Africa Market Overview

10.2 Middle East & Africa Market in Terms of Value

10.2.1 Market in Terms of Value (Normal Recovery)

10.2.2 Market in Terms of Value (V-Shaped Recovery)

10.2.3 Market in Terms of Value (W-Shaped Recovery)

10.2.4 Market in Terms of Value (U-Shaped Recovery)

10.2.5 Market in Terms of Value (L-Shaped Recovery)

10.3 Middle East & Africa Market Breakdown by Country

10.3.1 Market in Terms of Value (Normal Recovery)

10.3.2 Market in Terms of Value (V-Shaped Recovery)

10.3.3 Market in Terms of Value (W-Shaped Recovery)

10.3.4 Market in Terms of Value (U-Shaped Recovery)

10.3.5 Market in Terms of Value (L-Shaped Recovery)

10.4 Turkey Vaccine Sales Market Outlook

10.4.1 Market in Terms of Value (Normal Recovery)

10.4.2 Market in Terms of Value (V-Shaped Recovery)

10.4.3 Market in Terms of Value (W-Shaped Recovery)

10.4.4 Market in Terms of Value (U-Shaped Recovery)

10.4.5 Market in Terms of Value (L-Shaped Recovery)

10.5 Saudi Arabia Vaccine Sales Market Outlook

10.5.1.1 Healthcare is the third largest beneficiary behind education and military

10.5.1 Market in Terms of Value (Normal Recovery)

10.5.2 Market in Terms of Value (V-Shaped Recovery)

10.5.3 Market in Terms of Value (W-Shaped Recovery)

10.5.4 Market in Terms of Value (U-Shaped Recovery)

10.5.5 Market in Terms of Value (L-Shaped Recovery)

10.6 South Africa Vaccine Sales Market Outlook

10.6.1.1 Pneumonia vaccine alone used up 40% of South Africa’s total budget for vaccines

10.6.1 Market in Terms of Value (Normal Recovery)

10.6.2 Market in Terms of Value (V-Shaped Recovery)

10.6.3 Market in Terms of Value (W-Shaped Recovery)

10.6.4 Market in Terms of Value (U-Shaped Recovery)

10.6.5 Market in Terms of Value (L-Shaped Recovery)

10.7 Iran Vaccine Sales Market Outlook

10.7.1.1. Iran's vaccine industry, has a long history and international reputation

10.7.1 Market in Terms of Value (Normal Recovery)

10.7.2 Market in Terms of Value (V-Shaped Recovery)

10.7.3 Market in Terms of Value (W-Shaped Recovery)

10.7.4 Market in Terms of Value (U-Shaped Recovery)

10.7.5 Market in Terms of Value (L-Shaped Recovery)

10.8 UAE Vaccine Sales Market Outlook

10.8.1 Market in Terms of Value (Normal Recovery)

10.8.2 Market in Terms of Value (V-Shaped Recovery)

10.8.3 Market in Terms of Value (W-Shaped Recovery)

10.8.4 Market in Terms of Value (U-Shaped Recovery)

10.8.5 Market in Terms of Value (L-Shaped Recovery)

10.9 Rest of Middle East & Africa Vaccine Sales Market Outlook

10.9.1 Market in Terms of Value (Normal Recovery)

10.9.2 Market in Terms of Value (V-Shaped Recovery)

10.9.3 Market in Terms of Value (W-Shaped Recovery)

10.9.4 Market in Terms of Value (U-Shaped Recovery)

10.9.5 Market in Terms of Value (L-Shaped Recovery)

10.10 Middle East & Africa Market Breakdown by Disease Type

10.10.1 Market in Terms of Value (Normal Recovery)

10.10.2 Market in Terms of Value (V-Shaped Recovery)

10.10.3 Market in Terms of Value (W-Shaped Recovery)

10.10.4 Market in Terms of Value (U-Shaped Recovery)

10.10.5 Market in Terms of Value (L-Shaped Recovery)

10.11 Middle East & Africa Market Breakdown by Viral Diseases

10.11.1 Market in Terms of Value (Normal Recovery)

10.11.2 Market in Terms of Value (V-Shaped Recovery)

10.11.3 Market in Terms of Value (W-Shaped Recovery)

10.11.4 Market in Terms of Value (U-Shaped Recovery)

10.11.5 Market in Terms of Value (L-Shaped Recovery)

10.12 Middle East & Africa Market Breakdown by Vaccine Type

10.12.1 Market in Terms of Value (Normal Recovery)

10.12.2 Market in Terms of Value (V-Shaped Recovery)

10.12.3 Market in Terms of Value (W-Shaped Recovery)

10.12.4 Market in Terms of Value (U-Shaped Recovery)

10.12.5 Market in Terms of Value (L-Shaped Recovery)

10.13 Middle East & Africa Market Breakdown by Bacterial Disease

10.13.1 Market in Terms of Value (Normal Recovery)

10.13.2 Market in Terms of Value (V-Shaped Recovery)

10.13.3 Market in Terms of Value (W-Shaped Recovery)

10.13.4 Market in Terms of Value (U-Shaped Recovery)

10.13.5 Market in Terms of Value (L-Shaped Recovery)

10.14 Middle East & Africa Market Breakdown by Distribution Channel

10.14.1 Market in Terms of Value (Normal Recovery)

10.14.2 Market in Terms of Value (V-Shaped Recovery)

10.14.3 Market in Terms of Value (W-Shaped Recovery)

10.14.4 Market in Terms of Value (U-Shaped Recovery)

10.14.5 Market in Terms of Value (L-Shaped Recovery)

10.15 Middle East & Africa Market Breakdown by Age Group

10.15.1 Market in Terms of Value (Normal Recovery)

10.15.2 Market in Terms of Value (V-Shaped Recovery)

10.15.3 Market in Terms of Value (W-Shaped Recovery)

10.15.4 Market in Terms of Value (U-Shaped Recovery)

10.15.5 Market in Terms of Value (L-Shaped Recovery)

 

11. Latin America Vaccines Sales Market Outlook

11.1 Latin America Market Overview

11.2 Latin America Market in Terms of Value

11.2.1 Market in Terms of Value (Normal Recovery)

11.2.2 Market in Terms of Value (V-Shaped Recovery)

11.2.3 Market in Terms of Value (W-Shaped Recovery)

11.2.4 Market in Terms of Value (U-Shaped Recovery)

11.2.5 Market in Terms of Value (L-Shaped Recovery)

11.3 Latin America Market Breakdown by Country

11.3.1 Market in Terms of Value (Normal Recovery)

11.3.2 Market in Terms of Value (V-Shaped Recovery)

11.3.3 Market in Terms of Value (W-Shaped Recovery)

11.3.4 Market in Terms of Value (U-Shaped Recovery)

11.3.5 Market in Terms of Value (L-Shaped Recovery)

11.4 Brazil Vaccine Sales Market Outlook

11.4.1.1 The Brazilian human vaccines market is the largest in Latin America

11.4.1 Market in Terms of Value (Normal Recovery)

11.4.2 Market in Terms of Value (V-Shaped Recovery)

11.4.3 Market in Terms of Value (W-Shaped Recovery)

11.4.4 Market in Terms of Value (U-Shaped Recovery)

11.4.5 Market in Terms of Value (L-Shaped Recovery)

11.5 Mexico Vaccine Sales Market Outlook

11.5.1 Market in Terms of Value (Normal Recovery)

11.5.2 Market in Terms of Value (V-Shaped Recovery)

11.5.3 Market in Terms of Value (W-Shaped Recovery)

11.5.4 Market in Terms of Value (U-Shaped Recovery)

11.5.5 Market in Terms of Value (L-Shaped Recovery)

11.6 Nigeria Vaccine Sales Market Outlook

11.6.1.1 The market is expected to grow at a decent growth rate during forecast period

11.6.1 Market in Terms of Value (Normal Recovery)

11.6.2 Market in Terms of Value (V-Shaped Recovery)

11.6.3 Market in Terms of Value (W-Shaped Recovery)

11.6.4 Market in Terms of Value (U-Shaped Recovery)

11.6.5 Market in Terms of Value (L-Shaped Recovery)

11.7 Rest of Latin America Vaccine Sales Market Outlook

11.7.1 Market in Terms of Value (Normal Recovery)

11.7.2 Market in Terms of Value (V-Shaped Recovery)

11.7.3 Market in Terms of Value (W-Shaped Recovery)

11.7.4 Market in Terms of Value (U-Shaped Recovery)

11.7.5 Market in Terms of Value (L-Shaped Recovery)

11.8 Latin America Market Breakdown by Disease Type

11.8.1 Market in Terms of Value (Normal Recovery)

11.8.2 Market in Terms of Value (V-Shaped Recovery)

11.8.3 Market in Terms of Value (W-Shaped Recovery)

11.8.4 Market in Terms of Value (U-Shaped Recovery)

11.8.5 Market in Terms of Value (L-Shaped Recovery)

11.9 Latin America Market Breakdown by Viral Diseases

11.9.1 Market in Terms of Value (Normal Recovery)

11.9.2 Market in Terms of Value (V-Shaped Recovery)

11.9.3 Market in Terms of Value (W-Shaped Recovery)

11.9.4 Market in Terms of Value (U-Shaped Recovery)

11.9.5 Market in Terms of Value (L-Shaped Recovery)

11.10 Latin America Market Breakdown by Vaccine Type

11.10.1 Market in Terms of Value (Normal Recovery)

11.10.2 Market in Terms of Value (V-Shaped Recovery)

11.10.3 Market in Terms of Value (W-Shaped Recovery)

11.10.4 Market in Terms of Value (U-Shaped Recovery)

11.10.5 Market in Terms of Value (L-Shaped Recovery)

11.11 Latin America Market Breakdown by Bacterial Diseases

11.11.1 Market in Terms of Value (Normal Recovery)

11.11.2 Market in Terms of Value (V-Shaped Recovery)

11.11.3 Market in Terms of Value (W-Shaped Recovery)

11.11.4 Market in Terms of Value (U-Shaped Recovery)

11.11.5 Market in Terms of Value (L-Shaped Recovery)

11.12 Latin America Market Breakdown by Distribution Channel

11.12.1 Market in Terms of Value (Normal Recovery)

11.12.2 Market in Terms of Value (V-Shaped Recovery)

11.12.3 Market in Terms of Value (W-Shaped Recovery)

11.12.4 Market in Terms of Value (U-Shaped Recovery)

11.12.5 Market in Terms of Value (L-Shaped Recovery)

11.13 Latin America Market Breakdown by Age Group

11.13.1 Market in Terms of Value (Normal Recovery)

11.13.2 Market in Terms of Value (V-Shaped Recovery)

11.13.3 Market in Terms of Value (W-Shaped Recovery)

11.13.4 Market in Terms of Value (U-Shaped Recovery)

11.13.5 Market in Terms of Value (L-Shaped Recovery)

 

12. Vaccines Under Research & Development

12.1 Dengue Vaccine Research

12.1.1 Status of vaccine development

12.1.2 Challenges to Vaccine Development

12.1.3 WHO activities

12.2 Malaria vaccines

12.2.1 Status of vaccine development

12.3 HIV Vaccine Development

12.4 Meningitis Vaccine Development

12.5 Influenza vaccines

12.5.1 Influenza Vaccine Development

12.5.2 Status of Vaccine Development

12.5.3 Challenges to Vaccine Development

12.6 Tuberculosis Vaccine Development

12.7 Zika Virus Vaccine Product Development

12.7.1 Technical roadmap for Zika vaccine development

12.8 Group A Streptococcus

12.9 RSV Vaccine Research And Development

 

13. Leading Company Profiles

13.1 Recent Technologies and Companies

13.2 Market Share

13.3 AstraZeneca

13.3.1 AstraZeneca: Business Overview

13.3.2 AstraZeneca: Company Financial Profile

13.3.3 AstraZeneca: Product and Service Offerings

13.3.4 AstraZeneca: Recent Developments

13.4 Johnson & Johnson

13.4.1 Johnson & Johnson: Business Overview

13.4.2 Johnson & Johnson: Company Financial Profile

13.4.3 Johnson & Johnson: Product and Service Offerings

13.4.4 Johnson & Johnson: Recent Developments

13.5 Bavarian Nordic

13.5.1 Bavarian Nordic: Business Overview

13.5.2 Bavarian Nordic: Company Financial Profile

13.5.3 Bavarian Nordic: Product and Service Offerings

13.5.4 Bavarian Nordic: Recent Developments

13.6 Merck & Co.

13.6.1 Merck & Co.: Business Overview

13.6.2 Merck & Co.: Company Financial Profile

13.6.3 Merck & co.: Product and Service Offerings

ERVEBO

13.6.4 Merck & co.: Recent Developments

13.7 Takeda Pharmaceutical Company

13.7.1 Takeda Pharmaceutical Company: Business Overview

13.7.2 Takeda Pharmaceutical Company: Company Financial Profile

13.7.3 Takeda Pharmaceutical Company: Product and Service Offerings

13.7.4 Takeda Pharmaceutical Company: Recent Developments

13.8 Roche Holding AG

13.8.1 Roche Holding AG: Business Overview

13.8.2 Roche Holding AG: Company Financial Profile

13.8.3 Roche Holding AG: Product and Service Offerings

13.8.4 Roche Holding AG: Recent Developments

13.9 GlaxoSmithKline PLC (GSK)

13.9.1 GlaxoSmithKline PLC (GSK): Business Overview

13.9.2 GlaxoSmithKline PLC (GSK): Company Financial Profile

13.9.3 GlaxoSmithKline PLC (GSK): Product and Service Offerings

13.9.4 GlaxoSmithKline PLC (GSK): Recent Developments

13.10 Bayer Inc.

13.10.1 Bayer Inc.: Business Overview

13.10.2 Bayer Inc.: Company Financial Profile

13.10.3 Bayer Inc.: Product and Service Offerings

13.10.4 Bayer Inc.: Recent Developments

13.11 Eli Lilly and Company

13.11.1 Eli Lilly and Company: Business Overview

13.11.2 Eli Lilly and Company: Company Financial Profile

13.11.3 Eli Lilly and Company: Product and Service Offerings

13.11.4 Eli Lilly and Company: Recent Developments

13.12 Bristol-Myers Squibb

13.12.1 Bristol-Myers Squibb: Business Overview

13.12.2 Bristol-Myers Squibb: Company Financial Profile

13.12.3 Bristol-Myers Squibb: Product and Service Offerings

13.12.4 Bristol-Myers Squibb: Recent Developments

13.13 Pfizer Inc.

1.11.1 Pfizer Inc.: Business Overview

13.13.1 Pfizer Inc.: Company Financial Profile

13.13.2 Pfizer Inc.: Product and Service Offerings

13.13.3 Pfizer Inc.: Recent Developments

13.14 Emergent BioSolutions Inc.

13.14.1 Emergent BioSolutions Inc.: Business Overview

13.14.2 Emergent BioSolutions Inc.: Company Financial Profile

13.14.3 Emergent BioSolutions Inc.: Product and Service Offerings

13.14.4 Emergent BioSolutions Inc.: Recent Developments

13.15 Fresenius SE & Co KGaA

13.15.1 Fresenius SE & Co KGaA: Business Overview

13.15.2 Fresenius SE & Co KGaA: Company Financial Profile

13.15.3 Fresenius SE & Co KGaA: Product and Service Offerings

13.15.4 Fresenius SE & Co KGaA: Recent Developments

13.16 Sanofi

13.16.1 Sanofi: Business Overview

13.16.2 Sanofi: Company Financial Profile

13.16.3 Sanofi: Product and Service Offerings

13.16.4 Sanofi: Recent Developments

13.17 BiondVaxPharmaceuticals Ltd.

13.17.1 BiondVax Pharmaceuticals Ltd.: Business Overview

13.17.2 BiondVax Pharmaceuticals Ltd.: Company Financial Profile

13.17.3 BiondVax Pharmaceuticals Ltd.: Product and Service Offerings

13.17.4 BiondVax Pharmaceuticals Ltd.: Recent Developments

List of Figures

Figure 1.1 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.1 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.2 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 6.3 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 6.4 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 6.5 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 6.6 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.7 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 6.8 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 6.9 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 6.10 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 6.11 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.12 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 6.13 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 6.14 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 6.15 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 6.16 Global Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.17 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 6.18 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 6.19 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 6.20 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 6.21 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.22 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 6.23 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 6.24 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 6.25 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 6.26 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.27 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 6.28 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 6.29 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 6.30 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 6.31 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.32 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 6.33 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 6.34 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 6.35 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 6.36 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)

Figure 6.37 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 6.38 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 6.39 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 6.40 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 7.1 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)

Figure 7.2 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 7.3 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)(W-Shaped Recovery)

Figure 7.4 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 7.5 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 7.6 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)

Figure 7.7 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 7.8 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 7.9 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 7.10 North America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 7.11 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 7.12 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 7.13 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 7.14 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 7.15 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 7.16 North America Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 7.17 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 7.18 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 7.19 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 7.20 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 2.1 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 7.22 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 7.23 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 7.24 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 7.25 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 7.26 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 7.27 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 7.28 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 7.29 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 7.30 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 7.31 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)

Figure 7.32 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 7.33 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 7.34 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 7.35 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 7.36 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)

Figure 7.37 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 7.38 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 7.39 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 7.40 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 8.1 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)

Figure 8.2 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 8.3 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 8.4 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 8.5 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 8.6 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)

Figure 8.7 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 8.8 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 8.9 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 8.10 Europe Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 8.11 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 8.12 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 8.13 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 8.14 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 8.15 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 8.16 Europe Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 8.17 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 8.18 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 8.19 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 8.20 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 8.21 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 8.22 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 8.23 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 8.24 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 8.25 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 8.26 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 8.27 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 8.28 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 8.29 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 8.30 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 8.31 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)

Figure 8.32 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 8.33 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 8.34 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 8.35 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 8.36 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)

Figure 8.37 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 8.38 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 8.39 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 8.40 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 9.1 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)

Figure 9.2 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 9.3 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 9.4 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 9.5 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 9.6 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)

Figure 9.7 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 9.8 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 9.9 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 9.10 Asia-Pacific Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 9.11 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 9.12 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 9.13 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 9.14 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 9.15 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 9.16 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %)

Figure 9.17 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 9.18 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 9.19 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 9.20 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 9.21 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 9.22 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 9.23 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 9.24 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 9.25 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 9.26 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 9.27 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 9.28 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 9.29 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 9.30 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 9.31 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)

Figure 9.32 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 9.33 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 9.34 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 9.35 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 9.36 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)

Figure 9.37 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 9.38 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 9.39 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 9.40 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 10.1 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)

Figure 10.2 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 10.3 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 10.4 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 10.5 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 10.6 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)

Figure 10.7 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 10.8 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 10.9 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 10.10 Middle East & Africa Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 10.11 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 10.12 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 10.13 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 10.14 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 10.15 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 10.16 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %)

Figure 10.17 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 10.18 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 10.19 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 10.20 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 10.21 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 10.22 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 10.23 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 10.24 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 10.25 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 10.26 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 10.27 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 10.28 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 10.29 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 10.30 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 10.31 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)

Figure 10.32 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 10.33 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 10.34 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 10.35 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 10.36 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)

Figure 10.37 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 10.38 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 10.39 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 10.40 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 11.1 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.2 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 11.3 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 11.4 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.5 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 11.6 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.7 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 11.8 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 11.9 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.10 Latin America Vaccine Sales Market by Country Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 11.11 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.12 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.13 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 11.14 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.15 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 11.16 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.17 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 11.18 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 11.19 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.20 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 11.21 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.22 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 11.23 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 11.24 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.25 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.26 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.27 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 11.28 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 11.29 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.30 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 11.31 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.32 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 11.33 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 11.34 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.35 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 11.36 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %)

Figure 11.37 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (V-Shaped Recovery)

Figure 11.38 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (W-Shaped Recovery)

Figure 11.39 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (U-Shaped Recovery)

Figure 11.40 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %) (L-Shaped Recovery)

Figure 12.1 Dengue Vaccine Candidates in the Development

Figure 13.1 Global Vaccine Sales Market Share 2019 (%)

Figure13.2AstraZeneca: Company Revenue 2015-2019 (US$Mn, AGR %)

Figure13.3AstraZeneca: Company Operating Income 2015-2019 (US$Mn)

Figure13.4AstraZeneca: Company EBITDA 2015-2019 (US$Mn)

Figure13.5AstraZeneca: Company Net Income/Loss 2015-2019 (US$Mn)

Figure13.6Johnson & Johnson: Company Revenue 2015-2019 (US$Mn, AGR %)

Figure13.7Johnson & Johnson: Company Operating Income 2015-2019 (US$Mn)

Figure13.8Johnson & Johnson: Company EBITDA 2015-2019 (US$Mn)

Figure13.9 Johnson & Johnson: Company Net Income/Loss 2015-2019 (US$Mn)

Figure13.10Bavarian Nordic: Company Revenue 2015-2019 (US$Mn, AGR %)

Figure11.10Bavarian Nordic: Company Operating Income 2015-2019 (US$Mn)

Figure13.12Bavarian Nordic: Company EBITDA 2015-2019 (US$Mn)

Figure13.13Bavarian Nordic: Company Net Income/Loss 2015-2019 (US$Mn)

Figure131.141Bayer Inc.: Company EBITDA 2015-2019 (US$Mn)

Figure 13.15 Sanofi: Company Revenue 2015-2019 (US$Mn, AGR %)

Figure13.16Sanofi: Company Operating Income 2015-2019 (US$Mn)

Figure 13.17 Sanofi: Company EBITDA 2015-2019 (US$Mn)

Figure 13.18Sanofi: Company Net Income/Loss 2015-2019 (US$Mn)

 

List of Tables

---

Table 1.1 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 2.1 Global Vaccine Sales Market Summary Table

Table 3.1 History of Vaccines

Table 1.1 COVID-19 Therapeutic Interventions in Development, by Biopharmaceutical Company Collaborations

Table 1.1 COVID-19 Therapeutics in Development, by Biopharmaceutical Company

Table 1.1 COVID-19 Vaccines in Development by Biopharmaceutical Companies in Collaboration

Table 1.1 COVID-19 Vaccines in Development, by Biopharmaceutical Company

Table 6.1 UNICEF Vaccination Price and Major Suppliers, 2019

Table 6.2 Global Vaccine Price List, 2019

Table 6.3 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 6.4 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.5 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.6 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.7 Global Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.8 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 6.9 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.10 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.11 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.12 Global Vaccine Sales Market by Region Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.13 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 6.14 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.15 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.16 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.17 Global Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.18 Vaccine-Preventable Human Viral Diseases

Table 6.19 Vaccines, by Disease Type

Table 6.20 Seasonal Influenza Vaccines

Table 6.21 Global Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 6.22 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.23 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.24 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.25 Global Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.26 Types of Attenuated (Live) Vaccines

Table 6.27 Advantages and Disadvantages of Attenuated (Live) Vaccines

Table 6.28 Types of Inactivated (Killed) Vaccines

Table 6.29 Advantages and Disadvantages of Inactivated (Killed) Vaccines

Table 6.30 Types of Toxoid Vaccines

Table 6.31 Advantages and Disadvantages of Toxoid Vaccines

Table 6.32 Types of Subunit Vaccines

Table 6.33 Advantages and Disadvantages of Subunit Vaccines

Table 6.34 Types of Conjugate Vaccines

Table 5.30 Advantages and Disadvantages of Conjugate Vaccines

Table 6.36 Types of Recombinant Vector Vaccines

Table 6.37 Advantages and Disadvantages of Recombinant Vector Vaccines

Table 6.38 Types of DNA Vaccines

Table 6.39 Advantages and Disadvantages of DNA Vaccines

Table 6.40 Advantages and Disadvantages of RNA Vaccines

Table 6.41 Vaccine Excipient and Media Summary, Excipients included in U.S. Vaccines

Table 6.42 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 6.43 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.44 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.45 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.46 Global Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.47 Vaccine-Preventable Human Bacterial Diseases

Table 6.48 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 6.49 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.50 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.51 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.52 Global Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.53 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 6.54 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.55 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.56 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.57 Global Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 6.58 Pediatric Vaccines Doses

Table 6.59 Pediatric/VFC Vaccine Price List, 2019

Table 6.60 Pediatric Influenza Vaccine Price List

Table 6.61 Vaccines Dose by Age

Table 6.62 Adult Vaccine Price List

Table 6.63 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 6.64 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 6.65 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 6.66 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 6.67 Global Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.1 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.2 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.3 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.4 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.5 North America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.6 US Recommended Immunization Schedule, by Vaccine Type, 2020

Table 7.7 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.8 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.9 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.10 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.11 U.S. Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.12 Immunization Schedule of Canada, 2020

Table 7.13 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.14 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.15 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.16 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.17 Canada Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.18 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.19 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.20 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.21 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.22 North America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.23 North America Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.24 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.25 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.26 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.27 North America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.28 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.29 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.30 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.31 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.32 North America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.33 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.34 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.35 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.36 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.37 North America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.38 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.39 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.40 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.41 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.42 North America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 7.43 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 7.44 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 7.45 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 7.46 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 7.47 North America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.1 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.2 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.3 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.4 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.5 Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.6 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.7 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.8 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.9 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.10 Russia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.11 Immunization Schedule of Germany, 2020

Table 8.12 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.13 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.14 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.15 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.16 Germany Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.17 UK Vaccine Schedules

Table 8.18 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.19 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.20 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.21 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.22 UK Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.23 Immunization Schedule of France, 2020

Table 8.24 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.25 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.26 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.27 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.28 France Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.29 Immunization Schedule of Italy, 2020

Table 8.30 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.31 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.32 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.33 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.34 Italy Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.35 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.36 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.37 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.38 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.39 Rest of Europe Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.40 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.41 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.42 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.43 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.44 Europe Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.45 Europe Vaccine Sales Market by Viral Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.46 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.47 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.48 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.49 Europe Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.50 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.51 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.52 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.53 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.54 Europe Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.55 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.56 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.57 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.58 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.59 Europe Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.60 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.61 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.62 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.63 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.64 Europe Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 8.65 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 8.66 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 8.67 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 8.68 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 8.69 Europe Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.1 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.2 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.3 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.4 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.5 Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.6 Vaccination and Immunization Schedule of China, 2020

Table 9.7 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.8 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.9 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.10 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.11 China Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.12 Immunization Schedule of Japan, 2020

Table 9.13 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.14 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.15 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.16 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.17 Japan Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.18 Immunization Schedule of India, 2020

Table 9.19 GAVI Support to India, 2001-2021

Table 9.20 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.21 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.22 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.23 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.24 India Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.25 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.26 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.27 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.28 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.29 South Korea Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.30 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.31 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.32 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.33 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.34 Australia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.35 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.36 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.37 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.38 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.39 Rest of Asia-Pacific Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.40 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.41 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.42 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.43 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.44 Asia-Pacific Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.45 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.46 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.47 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.48 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.49 Asia-Pacific Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.50 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.51 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.52 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.53 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.54 Asia-Pacific Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.55 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.56 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.57 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.58 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.59 Asia-Pacific Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.60 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.61 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.62 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.63 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.64 Asia-Pacific Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 9.65 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 9.66 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 9.67 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 9.68 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 9.69 Asia-Pacific Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.1 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.2 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.3 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.4 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.5 Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.6 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.7 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.8 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.9 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.10 Turkey Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.11 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.12 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.13 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.14 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.15 Saudi Arabia Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.16 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.17 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.18 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.19 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.20 South Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.21 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.22 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.23 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.24 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.25 Iran Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.26 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.27 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.28 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.29 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.30 UAE Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.31 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.32 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.33 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.34 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.35 Rest of Middle East & Africa Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.36 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.37 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.38 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.39 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.40 Middle East & Africa Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.41 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.42 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.43 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.44 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.45 Middle East & Africa Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.46 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.47 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.48 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.49 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.50 Middle East & Africa Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.51 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.52 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.53 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.54 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.55 Middle East & Africa Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.56 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.57 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.58 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.59 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.60 Middle East & Africa Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 10.61 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 10.62 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 10.63 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 10.64 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 10.65 Middle East & Africa Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.1 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.2 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.3 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.4 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.5 Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.6 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.7 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.8 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.9 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.10 Brazil Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.11 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.12 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.13 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.14 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.15 Mexico Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.16 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.17 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.18 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.19 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.20 Nigeria Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.21 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.22 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.23 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.24 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.25 Rest of Latin America Vaccine Sales Market by Value Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.26 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.27 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.28 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.29 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.30 Latin America Vaccine Sales Market by Disease Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.31 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.32 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.33 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.34 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.35 Latin America Vaccine Sales Market by Viral Diseases Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.36 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.37 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.38 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.39 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.40 Latin America Vaccine Sales Market by Type Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.41 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.42 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.43 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.44 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.45 Latin America Vaccine Sales Market by Bacterial Disease Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.46 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.47 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.48 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.49 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.50 Latin America Vaccine Sales Market by Distribution Channel Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table 11.51 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %)

Table 11.52 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (V-Shaped Recovery)

Table 11.53 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (W-Shaped Recovery)

Table 11.54 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (U-Shaped Recovery)

Table 11.55 Latin America Vaccine Sales Market by Age Group Forecast 2020-2030 (US$ billion, AGR %, CAGR %) (L-Shaped Recovery)

Table13.1 AstraZeneca Company Information

Table13.2 AstraZeneca: Company Revenue 2015-2019 (US$Mn, AGR %)

Table13.3 AstraZeneca: Company Product and Service Offerings

Table13.4 AstraZeneca: Company Recent Developments till July,2020

Table13.5 Johnson & Johnson Company Information

Table13.6 Johnson & Johnson: Company Revenue 2015-2019 (US$Mn, AGR %)

Table13.7 Johnson & Johnson: Company Product and Service Offerings

Table13.8 Johnson & Johnson: Company Recent Developments till July,2020

Table13.9 Bavarian Nordic Company Information

Table13.10 Bavarian Nordic: Company Revenue 2015-2019 (US$Mn, AGR %)

Table13.11 Bavarian Nordic: Company Product and Service Offerings

Table13.12 Bavarian Nordic: Company Recent Developments till July,2020

Table13.13 Merck & Co.Company Information

Table13.14 Merck & Co.: Company Revenue 2015-2019 (US$Mn, AGR %)

Table13.15 Merck & co.: Company Product and Service Offerings

Table13.16 Merck & co.: Company Recent Developments till July,2020

Table13.17 Takeda Pharmaceutical: Company Information

Table13.18 Takeda Pharmaceutical Company: Company Revenue 2015-2019 (US$Mn, AGR %)

Table13.19 Takeda Pharmaceutical Company: Company Product and Service Offerings

Table13.20 Takeda Pharmaceutical Company: Company Recent Developments till July,2020

Table13.21 Roche Holding AG Company Information

Table113.22 Roche Holding AG: Company Recent Developments till July,2020

Table113.23 GlaxoSmithKline PLC (GSK) Company Information

Table131.24 GlaxoSmithKline PLC (GSK): Company Revenue 2015-2019 (US$Mn, AGR %)

Table113.25 GlaxoSmithKline PLC (GSK): Company Product and Service Offerings

Table113.26 GlaxoSmithKline PLC (GSK): Company Recent Developments till July,2020

Table113.27 Bayer Inc. Company Information

Table113.28 Bayer Inc.: Company Product and Service Offerings

Table131.29 Bayer Inc.: Company Recent Developments till July,2020

Table113.30 Eli Lilly and Company Company Information

Table113.31 Eli Lilly and Company: Company Revenue 2015-2019 (US$Mn, AGR %)

Table113.32 Eli Lilly and Company: Company Product and Service Offerings

Table113.33 Eli Lilly and Company: Company Recent Developments till July,2020

Table113.34 Bristol-Myers Squibb Company Information

Table131.35 Bristol-Myers Squibb: Company Revenue 2015-2019 (US$Mn, AGR %)

Table113.36 Bristol-Myers Squibb: Company Product and Service Offerings

Table113.37 Bristol-Myers Squibb: Company Recent Developments till July,2020

Table 13.38 Pfizer Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)

Table13.39 Pfizer Inc.: Company Product and Service Offerings

Table13.40 Pfizer Inc.: Company Recent Developments till July,2020

Table 13.41 Emergent BioSolutions Inc. Company Information

Table 13.42 Emergent BioSolutions Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)

Table 13.43 Emergent BioSolutions Inc.: Company Product and Service Offerings

Table 13.44 Emergent BioSolutions Inc.: Company Recent Developments till July,2020

Table 13.45 Fresenius SE & Co KGaA Company Information

Table 11.50 Fresenius SE & Co KGaA: Company Revenue 2015-2019 (US$Mn, AGR %)